Back

Dual or single anti-thrombotic therapy in patients with atrial fibrillation after TAVI: a pre-specified analysis from the ENVISAGE-TAVI AF trial

19 February 2026 (08:00 - 18:30)
Organised by: Logo
Congress Presentation Part of: Poster session (2) - Pharmacology and pharmacotherapy Antiplatelet Drugs EAPCI Premium Access EAPCI Summit 2026 European Association of Percutaneous Cardiovascular Interventions (EAPCI)

About the speaker

Photo
Professor Marco Valgimigli

Cardiocentro Ticino Institute, Lugano (Switzerland)

4 More presentations in this session

Presentation thumbnail
Sex differences among elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention receiving ticagrelor 60 mg vs. 90 mg: a post-hoc analysis of a randomized trial
Doctor A. Laino (Naples, IT)
Abstract Slides
Presentation thumbnail
Clopidogrel versus aspirin as long-term monotherapy after PCI with drug-eluting stents: a systematic review and meta-analysis
Doctor A. Emara (Menoufia, EG)
Abstract
Presentation thumbnail
Plasma metabolomic profiling of patients with acute coronary syndrome treated with potent platelet inhibitors
Mr J. Rogozarski (Vienna, AT)
Abstract Slides
Presentation thumbnail
Discussant - Pharmacology and pharmacotherapy

Access the full session

Session thumbnail
Poster session (2) - Pharmacology and pharmacotherapy

The Event

Event poster

EAPCI Summit 2026

19 February - 20 February 2026
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources